BiotechTube

NEX-18a injection + Azacitidine Injection

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes (MDS)

Conditions

Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)

Trial Timeline

Apr 27, 2021 → Feb 10, 2022

NCT ID
NCT05048498

About NEX-18a injection + Azacitidine Injection

NEX-18a injection + Azacitidine Injection is a phase 1 stage product being developed by Nanexa AB for Myelodysplastic Syndromes (MDS). The current trial status is completed. This product is registered under clinical trial identifier NCT05048498. Target conditions include Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML).

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05048498Phase 1Completed

Competing Products

20 competing products in Myelodysplastic Syndromes (MDS)

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
decitabine + azacitidineEisaiApproved
85
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
Subcutaneous DecitabineEisaiPhase 1
33
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
DecitabineJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52
DecitabineJohnson & JohnsonPhase 2
52

Other Products from Nanexa AB

NEX-20APhase 1
28
NEX-22A, a prolonged release formulation of liraglutidePhase 1
28